[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554256":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":67,"collaborators":71,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":19,"eligibilityCriteria":80,"healthyVolunteers":77,"sex":81,"minAge":82,"maxAge":19,"enrollmentInfo":83,"targetDuration":19,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Jinling Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Albumin paclitaxel\u002Fneutrophil drug","EXPERIMENTAL","Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. Then the drug will be infused intravenously into patients. The number of neutriphil cells will be more than 1.0E10.",[13],"Biological: Albumin paclitaxel\u002Fneutrophil drug",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel\u002Fneutrophil drug.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Jia Shaochang, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Jiang Longwei, Master","CONTACT","+86-02580864524","jianglw2005@163.com",[31,48],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Jinling Hospital","RECRUITING","Nanjing","Jiangsu","210002","China","CN",{"type":40,"coordinates":41},"Point",[42,43],118.77778,32.06167,{"lat":43,"lon":42},[46],{"name":26,"role":27,"phone":47,"phoneExt":19,"email":29},"+86-80864524",{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},{"type":40,"coordinates":50},[42,43],{"lat":43,"lon":42},[53,55,59,62,63,65],{"name":26,"role":27,"phone":54,"phoneExt":19,"email":29},"+862580864524",{"name":56,"role":27,"phone":57,"phoneExt":19,"email":58},"JIA SHAOCHANG, MD","+86-13905169358","jiashaochang@sina.com",{"name":60,"role":61,"phone":19,"phoneExt":19,"email":19},"ZHANG CAN, PhD","SUB_INVESTIGATOR",{"name":56,"role":61,"phone":19,"phoneExt":19,"email":19},{"name":64,"role":61,"phone":19,"phoneExt":19,"email":19},"JU CAOYUN, PhD",{"name":66,"role":61,"phone":19,"phoneExt":19,"email":19},"YAO LU, Master",{"type":68,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","JIANG LONGWEI","associate researcher",[72],{"name":73,"class":74},"China Pharmaceutical University","UNKNOWN","100554256","a-clinical-study-of-albumin-bound-paclitaxelgranulocyte-based-therapy-for-recurrentmetastatic-breast-cancer-100554256",false,"NCT06496724","A Clinical Study of Albumin-bound Paclitaxel\u002FGranulocyte-based Therapy for Recurrent\u002FMetastatic Breast Cancer","Inclusion Criteria:\n\n* Female, aged ≥ 18 years old; Obtain an informed consent form voluntarily signed by the patient themselves; Recurrent\u002Fmetastatic advanced breast cancer patients (refer to TNM standard); Patients who have received standard first-line treatments and expected survival time ≥ 3 months; EOCG score ≤ 2 and KPS≥ 70 points; Liver, kidney and bone marrow functions are basically normal; Patients of childbearing age need to take appropriate protective measures before enrollment and after treatment 3 months.\n\nExclusion Criteria:\n\n* Individuals who have received other anti-tumor treatment within 4 weeks prior the enrollment; Patients with history of allergy to paclitaxel, albumin naproxen, ibuprofen, trimethoprim and ampicillin; Positive blood pregnancy test; Patients who required anti coagulant therapy; Patients with active infectious diseases or a history of bone marrow or organ transplantation","FEMALE","18 Years",{"count":84,"type":85},1,"ESTIMATED","INTERVENTIONAL",[88],"NA","The goal of this clinical trial is to learn if Albumin-bound Paclitaxel\u002FGranulocyte drug can treat patients with recurrent\u002Fmetastatic breast cancer. The main questions it aims to answer are:\n\nTo verify the safety of Albumin-bound Paclitaxel\u002FGranulocyte drug in patients with recurrent\u002Fmetastatic breast cancer.\n\nTo evaluate the efficacy of Albumin-bound Paclitaxel\u002FGranulocyte drug in patients with recurrent\u002Fmetastatic breast cancer.\n\nTo detect the pharmacokinetic behavior of Albumin-bound Paclitaxel\u002FGranulocyte drug in patients with recurrent\u002Fmetastatic breast cancer.",[91],"Breast Cancer","2025-02-10",{"date":94,"type":95},"2025-02-12","ACTUAL",{"date":97,"type":95},"2024-06-01",{"date":99,"type":85},"2025-07-01",{"name":69,"class":6},2]